Medpace Holdings, Inc. $MEDP Shares Sold by Prakash Investment Advisors LLC

Prakash Investment Advisors LLC reduced its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 65.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 610 shares of the company’s stock after selling 1,140 shares during the quarter. Prakash Investment Advisors LLC’s holdings in Medpace were worth $314,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of MEDP. Wasatch Advisors LP raised its position in Medpace by 14.0% in the second quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock worth $296,853,000 after acquiring an additional 116,354 shares in the last quarter. Mawer Investment Management Ltd. increased its holdings in shares of Medpace by 17.4% during the 2nd quarter. Mawer Investment Management Ltd. now owns 817,432 shares of the company’s stock worth $256,559,000 after purchasing an additional 121,213 shares during the period. AQR Capital Management LLC raised its stake in shares of Medpace by 15.1% in the 2nd quarter. AQR Capital Management LLC now owns 621,184 shares of the company’s stock valued at $193,269,000 after buying an additional 81,637 shares in the last quarter. Baillie Gifford & Co. grew its holdings in shares of Medpace by 12.0% in the 3rd quarter. Baillie Gifford & Co. now owns 584,796 shares of the company’s stock worth $300,679,000 after purchasing an additional 62,503 shares during the last quarter. Finally, Epoch Investment Partners Inc. raised its stake in shares of Medpace by 11.4% in the second quarter. Epoch Investment Partners Inc. now owns 445,231 shares of the company’s stock worth $139,740,000 after acquiring an additional 45,435 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Insiders Place Their Bets

In other Medpace news, VP Susan E. Burwig sold 20,000 shares of the company’s stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $609.15, for a total transaction of $12,183,000.00. Following the sale, the vice president directly owned 27,500 shares of the company’s stock, valued at $16,751,625. This represents a 42.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO August J. Troendle sold 59,025 shares of Medpace stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $607.78, for a total transaction of $35,874,214.50. Following the completion of the transaction, the chief executive officer owned 774,602 shares of the company’s stock, valued at $470,787,603.56. The trade was a 7.08% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 201,745 shares of company stock worth $122,369,738 in the last ninety days. Insiders own 20.30% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Medpace in a research note on Wednesday, January 28th. Truist Financial decreased their price target on shares of Medpace from $555.00 to $539.00 and set a “hold” rating on the stock in a research note on Wednesday, February 11th. Leerink Partners dropped their price objective on Medpace from $575.00 to $485.00 and set a “market perform” rating for the company in a report on Wednesday, February 11th. Robert W. Baird upgraded Medpace from a “neutral” rating to an “outperform” rating and set a $564.00 target price for the company in a research report on Tuesday, February 10th. Finally, Mizuho set a $582.00 target price on shares of Medpace in a research report on Wednesday, February 11th. Four equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Medpace currently has an average rating of “Hold” and an average price target of $483.45.

Medpace Stock Performance

Shares of NASDAQ MEDP opened at $446.44 on Friday. The firm’s 50-day simple moving average is $558.09 and its 200 day simple moving average is $537.81. Medpace Holdings, Inc. has a fifty-two week low of $250.05 and a fifty-two week high of $628.92. The stock has a market cap of $12.67 billion, a price-to-earnings ratio of 29.18, a PEG ratio of 2.14 and a beta of 1.42.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Monday, February 9th. The company reported $4.67 EPS for the quarter, beating analysts’ consensus estimates of $4.18 by $0.49. The company had revenue of $708.45 million during the quarter, compared to the consensus estimate of $689.53 million. Medpace had a return on equity of 118.82% and a net margin of 17.83%.Medpace’s revenue was up 32.0% on a year-over-year basis. During the same period last year, the business posted $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, sell-side analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.